Pages: 223-228DOI: 10.46327/msrjg.1.000000000000064
Date of Publication: 30-Nov--0001
Hepatocellular Carcinoma Screening Is Indicated Even After Sustained Virological Response: -Moroccan University Hospital Experience-
Author: Y.Cherradi, R. Afifi, H. Benbrahim, O. H. El Malki, M. Benazzouz, A. Essaid
Category: JMSR Oncology
Introduction: Hepatitis C is the first aetiologic agent for HCC in Morocco. Antiviral treatment reduces the risk of developing HCC in patients with chronic hepatitis C but few cases of HCC have been still reported. We aimed to define population with high risk of HCC occurrence, confirm the protective role of SVR and to identify predictive factors of developing HCC after SVR. We__ampersandsign#39;ll try to present suggestions about screening strategies (indications and interval) after antiviral therapy according to level of HCC occurrence risk. Patients and Methods: We included all patients with chronic hepatitis C treated in our department from January 2002 to April 2010. We compare HCV-treated patients with no developed HCC to HCC population using khi-2 and Fisher Exact analysis. Results: 369 patients treated for hepatitis C were considered, and 20 HCC were reported. The risk of HCC occurrence was not significant according to gender and genotypes. Advanced age and severe fibrosis were significant risk factors. HCC was reported in 2.3% of sustained virological responders versus 12.5% of non responders. SVR is a significant protective factor. Conclusion: In our series, 5% of previously treated HCV carriers developed HCC and 2.3% of sustained virological responders developed. Achieving SVR after antiviral therapy is a protective factor. Advanced age (> 50 y. o), severe fibrosis (F>2) and lack of SVR at HCV diagnosis are predictive factors of HCC development in treated patients. Regular bi-annual ultrasonography screening should be indicated necessarily in patients with advanced fibrosis stage (F3- F4) even after SVR, particularly when co-morbid conditions are associated (advanced age, NASH, diabetes mellitus,...). Screening interval in sustained virological responders with reduced fibrosis stage may be limited to annual surveillance. Establishing guidelines about consensual strategy to survey sustained virological responders is now necessary especially with high rates of SVR and the extension of treatment indications in era of DAA drugs.
Keywords: Hepatocellular Carcinoma (HCC), Screening, Sustained Virological Response (SVR)
1-Epidemiology, natural history and pathogenesis ofhepatocellular carcinoma. Maillard E. CancerRadiother. 2011 Feb; 15 (1):3-6.
2-Bahri O, Ezzikouri S, Ben Alaya-Bouafif N, Iguer F,A. E. Essaid A. E, Mestir H, and all. First multicenterstudy for risk factors for hepatocellular carcinomadevelopment in North Africa, World J Hepatol 2011January 27; 3(1): 24-30
3-Hoshida Y, Fuchs BC, Bardeesy N, BaumertTF, Chung RT. Pathogenesis and prevention ofhepatitis C virus-induced hepatocellular carcinoma. JHepatol. 2014 November; 61(1 Suppl): S79-S90. doi:10.1016/j.jhep.2014.07.010
4-Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virusin the Maghreb Region: Systematic Review andMeta-Analyses. Thorne C, ed. PLoS ONE.2015;10(3):e0121873. doi:10.1371/journal.pone.0121873.
5-Baha W, Foullous A, Dersi N, Paluku T, El AlaouiK, Nourichafi N, and all. Prevalence and risk factorsof hepatitis B and C virus infections among thegeneral population and blood donors in Morocco.BMC Public Health BMC series 2013.DOI: 10.1186/1471-2458-13-50
6-Rioche M, Himmich H, Cherkaoui A, Mourid A,Dubreuil P, Zahraoui M, and al. High incidence ofsporadic non-A, non-B hepatitis in Morocco:epidemiologic study. Forte incidence des hepatitesnon-A, non-B sporadiques au Maroc: etudeepidemiologique. Bulletin de la Societe de pathologieexotique (1990). 1991;84(2):117-27.
7-Ezzikouri S, El Feydi AE, Afifi R, El Kihal L,Benazzouz M, Hassar M, et al. MDM2 SNP309T>Gpolymorphism and risk of hepatocellular carcinoma:a case-control analysis in a Moroccanpopulation.Cancer detection and prevention. 2009;32(5-6):380-5. Epub 2009/02/24.doi: 10.1016/j.cdp.2009.01.003
8-Hashem B. El-Serag. N Engl J Med 2011; 365:1118-1127September 22, 2011 DOI:10.1056/NEJMra1001683
9-Bahri O, Ezzikouri S, Ben Alaya-Bouafif N, Iguer F,A.Essaid A. E, Mestiri H, and all. Factors forhepatocellular carcinoma development in the NorthAfrica. Arab Journal of Gastroenterology, Volume10, Issue 2, June 2009, Page AB15doi:10.1016/j.ajg.2009.07.023
10-Younès Cherradi, Rajaa Afifi, Hanaa Benbrahim, etal., "Predictors of Developing HepatocellularCarcinoma in Treated HCV-Carriers in Moroccoaccording to University Hospital Experience," ISRNHepatology, vol. 2013, Article ID 438306, 3 pages,2013. doi:10.1155/2013/438306
11-Michielsen PP, Francque SM, van Dongen JL. Viralhepatitis and hepatocellular carcinoma. World J SurgOncol. 2005 May 20; 3: 27.
12-Minerva, De Nicola S1, Colombo M. The eradicationof HCV. Gastroenterol Dietol. 2015 Oct 7.
13-Asahina Y, Nihon R. Anti-HCV treatment for olderpatients. 2015 Feb; 73(2):292-8.
14--Serag, Hashem B. "Epidemiology of Viral Hepatitisand Hepatocellular Carcinoma. Gastroenterology142.6 (2012): 1264-1273.e1. PMC. Web. 29 May2016.
15-Toyoda H, Tada T, Tsuji K, Hiraoka A, TachiY, Itobayashi E , and all. Characteristics andPrognosis of Hepatocellular Carcinoma Detected inPatients with Chronic Hepatitis C after theEradication of Hepatitis C Virus: a Multicenter Studyfrom Japan. Hepatol Res. 2015 Oct 27. doi:10.1111/hepr.12613.
16-Pellicoro A, Prakash Ramachandran P. andJohn P Iredale J. P. Reversibility of liver fibrosis.Fibrogenesis & Tissue Repair 2012 5 (Suppl 1):S26DOI: 10.1186/1755-1536-5-S1-S26
17-Farrell GC, Chan HL, Yuen MF, Amarapurkar DN,Chutaputti A, and al. Prevention of hepatocellularcarcinoma in the Asia-Pacific region: consensusstatements. Asia-Pacific Working Party onPrevention of Hepatocellular Carcinoma. JGastroenterol Hepatol. 2010 Apr; 25(4):657-63.18-Vallet-Pichard A, Pol S, Mallet V. Assessmentand reversibility of liver fibrosis in viral hepatitis.Rev Prat. 2011 Jan; 61(1):39-43.